SamanTree Medical, a leading medical technology company specializing in surgical advancements, has secured $14 million in a Series B financing round. The funds will be allocated to advance and market their groundbreaking Histolog® Scanner, boost their presence in Europe and the US and enhance their digital offerings.
The Histolog Scanner, a CE-marked device, offers real-time intra-operative tissue assessment during surgery through high-resolution imaging. This allows pathologists and surgeons to make more informed decisions faster than traditional methods.
Relyens Innovation Santé, advised by Turenne Capital, led the funding round, with participation from Mutuelles Impact, Wille Finance, Noshaq, and WE Life Sciences, as well as existing investors Panakès Partners, BOM, and b2venture. SamanTree Medical will establish its headquarters and operations base in Wallonia, Belgium, while retaining its R&D facilities in Lausanne, Switzerland.
Claire Poulard, Investment Director at Turenne Capital, and Henry Charlton, SVP and Chief Commercial Officer at Intuitive, have joined the Board of Directors. The company is optimistic that the funding and strengthened leadership will accelerate innovation, global expansion, and digital solution enhancement, ultimately improving patient outcomes.
The Walloon investors WE Life Sciences and Noshaq have expressed their ongoing support for SamanTree Medical and their commitment to strengthening the local life sciences ecosystem. The company’s focus on advancing surgical techniques with technology underscores its commitment to revolutionizing the field of surgery.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
